SEC Company Response from Aktis Oncology, Inc. (AKTS) (CIK 0002035832) — Jan 6, 2026
Aktis Oncology, Inc. (AKTS) (CIK 0002035832)
Date: Jan. 6, 2026 · CIK: 0002035832 · Accession: 0001193125-26-004378
AI Filing Summary & Sentiment
File numbers found in text: 333-292283
Letter
January 6, 2026
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tyler Howes
Alan Campbell
Re: Aktis Oncology, Inc.
Acceleration Request for Aktis Oncology, Inc.
Registration Statement on Form S-1
File No. 333-292283
Ladies and Gentlemen:
We refer to the registration statement on Form S-1 (File No. 333-292283) (as amended, the “Registration Statement”), of Aktis Oncology, Inc. (the “Company”), relating to the registration of the Company’s common stock, par value $0.0001 per share.
In accordance with Rules 460 and 461 under the Securities Act of 1933, as amended, (the “Act”) we, as representatives of the several underwriters (the “Underwriters”), hereby respectfully request that the effectiveness of the Registration Statement be accelerated so that it may become effective at 4:00 PM (Eastern time) on January 8, 2026, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others prior to the requested effective time of the Registration Statement.
We, the undersigned, as representatives of the several Underwriters, have complied and will comply, and we have been informed by the participating Underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]
Very truly yours,
J.P. MORGAN SECURITIES LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP January 6, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes Alan Campbell Re: Aktis Oncology, Inc. Acceleration Request for Aktis Oncology, Inc. Registration Statement on Form S-1 File No. 333-292283 Ladies and Gentlemen: We refer to the registration statement on Form S-1 (File No. 333-292283) (as amended, the “Registration Statement”), of Aktis Oncology, Inc. (the “Company”), relating to the registration of the Company’s common stock, par value $0.0001 per share. In accordance with Rules 460 and 461 under the Securities Act of 1933, as amended, (the “Act”) we, as representatives of the several underwriters (the “Underwriters”), hereby respectfully request that the effectiveness of the Registration Statement be accelerated so that it may become effective at 4:00 PM (Eastern time) on January 8, 2026, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others prior to the requested effective time of the Registration Statement. We, the undersigned, as representatives of the several Underwriters, have complied and will comply, and we have been informed by the participating Underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Signature Page Follows] Very truly yours, J.P. MORGAN SECURITIES LLC BOFA SECURITIES, INC. LEERINK PARTNERS LLC TD SECURITIES (USA) LLC As representatives of the several underwriters J.P. MORGAN SECURITIES LLC By: /s/ Brandon Petillo Name: Brandon Petillo Title: Executive Director BOFA SECURITIES, INC. By: /s/ Greg Butz Name: Greg Butz Title: Co-Head of Global Healthcare Investment Banking, Managing Director LEERINK PARTNERS LLC By: /s/ Sean Pitt Name: Sean Pitt Title: Senior Managing Director TD SECURITIES (USA) LLC By: /s/ Brian Hagerty Name: Brian Hagerty Title: Managing Director [Signature Page to Acceleration Request]